HEALTH TECHNOLOGY

Murata Vios Announces Integration with PointClickCare’s EHR Platform

Murata Vios, Inc | June 24, 2022

Murata Vios

Murata Vios, Inc., developer of the Vios Monitoring System, is proud to announce the launch of its integration with PointClickCare, the leading cloud‐based software vendor for the senior care market. The integration will allow healthcare facilities to seamlessly integrate vital signs data into residents’ electronic health records for clinical review, helping to eliminate data entry time lags, transcription errors, and improve clinician efficiency.

Real‐time understanding of a resident’s vital signs can help prevent hospital readmissions because care teams can more quickly identify and treat the early signs of clinical deterioration. With the Vios Monitoring System and its Remote Monitoring Services, PointClickCare customers have a better way to capture this data and respond to changes in a resident’s condition. It can also free up clinical time that was previously spent on manually spot‐checking and recording vital signs every few hours.”

Amit Patel, CEO of Murata Vios

The Vios Monitoring System is a wireless, FDA‐cleared patient monitoring platform designed to improve resident safety and outcomes. The system delivers insights and value to post‐acute care providers by

  • Continuously monitoring vital signs. The Vios Monitoring System measures high‐fidelity 7‐lead ECG, heart rate, oxygen levels, pulse rate, respiratory rate, and posture data.
  • Improving 24/7/365 oversight of changes in resident conditions. With Vios Remote Monitoring Services, a team of cardiac‐trained technicians can alert the on‐site care team to any changes in a resident’s condition, enabling them to quickly respond to resident deterioration that could lead to readmission.
  • Identifying risk of pressure injuries. The Vios Chest Sensor has a built‐in 3‐axis accelerometer that detects and displays the resident’s posture in real‐time. When turn orders are added, the system can determine when a patient is at‐risk of developing a pressure injury so the on‐site care team can address the issue.

Additional information regarding the integration can be found on the PointClickCare Marketplace – an online platform that enables customers to easily evaluate authorized third-party technology partners. Partners listed on the PointClickCare Marketplace offer integrated apps and/or services that are designed to be quickly deployed and work seamlessly with providers’ existing workflows.

“The PointClickCare Marketplace offers the widest range of integrated solutions available to the market,” says Chris Beekman, Marketplace Director, PointClickCare. “Our partnership with Murata Vios is further testament to our continually growing partner network and ecosystem, and the wealth of possibilities it provides our customers to extend their technology capabilities.”

About Murata Vios, Inc.

Murata Vios, Inc., a subsidiary of Murata Manufacturing Co., Ltd., developed the Vios Monitoring System (VMS) to improve patient outcomes and reduce costs across the care continuum. Healthcare facilities can use the wireless, FDA‐cleared vital signs monitoring solution on existing IT infrastructure and instantly deploy the VMS to meet the acuity needs of patients across various care settings. Vios Remote Monitoring Services support healthcare teams with real‐time patient event analysis and notifications, helping to maximize patient safety while minimizing the burden on stretched clinical staff. 

About PointClickCare

PointClickCare is a leading healthcare technology platform enabling meaningful collaboration and access to real‐time insights at any stage of a patient’s healthcare journey. PointClickCare’s single platform spans the care continuum, fostering proactive, holistic decision‐making and improved outcomes for all. Over 22,000 long‐term post‐acute care providers, and 1,600 hospitals use PointClickCare today, enabling care collaboration and value‐based care delivery for millions of lives across North America.

Spotlight

Steven Manoukian, MD, FAHA, FACC, FSCAI, Senior Vice President of Strategic Service Lines at HCA Healthcare on the link between cardiology and stroke management and how HCA Healthcare is teaming up with the American Heart Association in leading the charge on this important issue in Florida and across the nation.

Spotlight

Steven Manoukian, MD, FAHA, FACC, FSCAI, Senior Vice President of Strategic Service Lines at HCA Healthcare on the link between cardiology and stroke management and how HCA Healthcare is teaming up with the American Heart Association in leading the charge on this important issue in Florida and across the nation.

Related News

FUTURE OF HEALTHCARE, MEDICAL DEVICES

Greenway Health introduces GEM program to boost clients’ healthcare IT journey

Greenway Health | December 29, 2022

Greenway Health, a leading provider of health information technology services, has recently launched the Greenway Engagement Model (GEM), a new client engagement program. Through intentional interaction and strategic support, the program is intended to strengthen Greenway's trusted advisor relationship with clients and support a more successful healthcare technology journey for Greenway clients. The GEM program offers a dedicated client support team, which develops a client feedback program focused on improving the user experience and patient outcomes, reducing clinician burnout, and advancing technology that best serves healthcare providers. The program is focused on creating an upgraded experience not yet seen in the healthcare IT industry. Clients will benefit from value-added services like clinical and revenue cycle assessments with optimization recommendations, benchmarking, and tracking of client-specific KPIs (key performance indicators) to help their practice grow. This is one of the most integrated customer engagement programs ever launched by Greenway Health. In order to provide a top-notch experience, each client will also receive simplified engagement from the Greenway team, including executive or senior leader sponsorship. The company firmly believes in bringing trust, loyalty, and knowledge to its customers, which necessitates a tailored engagement model that creates a user-friendly platform for the customers to share their experiences and receive hands-on support. GEM's overarching objective is to make sure that its clients enjoy fruitful cooperation with Greenway in the area of healthcare technology so that they can return to doing what they do best—serving patients. About Greenway Health Greenway Health provides cutting-edge technology, first-rate services, and strategic alliances with the aim of assisting clients in achieving success. The clinical, financial, and technology experts employed at Greenway are committed to creating cutting-edge solutions that maintain people's well-being. As a consequence of Greenway's partnerships with businesses and innovative service providers across numerous industries, its solutions have a daily impact on millions of lives.

Read More

HEALTHTECH SECURITY, DIGITAL HEALTHCARE

CHA Hollywood Presbyterian Medical Center Launches Fetal Surgery Program

CHA Hollywood Presbyterian Medical Center | January 23, 2023

Hollywood Presbyterian Medical Center (CHA HPMC), a member of CHA Health Systems, recently announced a new partnership with Los Angeles Fetal Surgery to provide life-saving and revolutionary fetal surgery to pregnant women and their unborn babies with birth defects. It will be the only fetal surgery center in the U.S. Los Angeles Fetal Surgery, a joint program between USC and Children's Hospital Los Angeles, offers minimally invasive fetal treatments to reduce or cure adverse outcomes due to fatal conditions, which would otherwise result in the baby's death or irreversible organ damage. Dr. Ramen Chmait, an international expert in minimally invasive fetal surgery, will direct the program. He has produced over 200 manuscripts and book chapters in fetal medicine and surgery over the past 20 years. "The goal of the Los Angeles Fetal Surgery Program at CHA Hollywood Presbyterian is to treat unborn babies with innovative treatments while providing families with emotional support," said Ramen Chmait, MD, who also serves as an OB-GYN with Keck Medicine of USC. (Source- Business Wire) "Our collaborative structure ensures our patients have access to a wide variety of services and specialists. This affiliation with CHA HPMC only strengthens our commitment to successful outcomes,” he further added. (Source- Business Wire) According to the CDC, 1 in 33 U.S. newborns is born with a serious condition. The program will treat Spina Bifida, Vasa Previa, and Twin-Twin Transfusion Syndrome. CHA HPMC, Los Angeles' second-largest maternity center, provides excellent prenatal and postpartum care. Fetal surgery will help CHA HPMC serve its community and improve results for expectant families. About CHA Hollywood Presbyterian Medical Center CHA Hollywood Presbyterian Medical Center (CHA HPMC) is a full-service hospital, providing acute care to the multicultural population of Hollywood and its neighboring regions since 1924. CHA Bio Group is known worldwide for its high-quality health care and advances in reproductive medicine. CHA HPMC has 469 acute care beds and 89 skilled nursing beds. The hospital employs about 550 doctors from 69 disciplines and 75 nationalities. It treats its various multicultural patients with kindness and compassion. CHA Health Systems, a dynamic global healthcare corporation with 86 hospitals and clinics, 30 research and 14 education institutes, along with 31 bio/pharmaceutical/healthcare enterprises, provides a wide range of services in seven countries.

Read More

FUTURE OF HEALTHCARE, MEDICAL DEVICES

LivaNova Launches Implantable Pulse Generator, SenTiva Duo, for Epilepsy

LivaNova | February 03, 2023

On February 02, 2023, LivaNova PLC, a medical innovation and technology company, has launched an implantable pulse generator (IPG) SenTiva DUO™, useful for VNS Therapy™ of drug-resistant epilepsy. With a dual-pinned header, it offers similar therapeutic benefits as SenTiva, the company's earlier product, which stimulates a response to the rapid heart rate, which can be a result of seizures, the low heart rate, and similar situations with day and night programming and scheduled programming. It recently received 510(k) clearance from the United States Food and Drug Administration and is now available for purchase in the United States. Professor and Chief Pediatric Neurology at Le Bonheur Children's Hospital in Memphis, Tennessee, Dr. James Wheless, said, "This new offering enables those VNS Therapy patients with legacy dual-pin systems to have the option to replace their device with SenTiva DUO, delivering the most advanced VNS Therapy treatment without the need for lead revision." He added, "Having access to SenTiva DUO offers patients therapy that can be customized and delivered automatically, providing optimal seizure control and enabling maximum adherence to treatment." (Source – Business Wire) Chief Executive Officer of LivaNova, Damien McDonald, said, "We're proud to offer SenTiva DUO to serve patients who were early adopters of VNS Therapy many years ago. Over time, all VNS Therapy patients must replace their generators as batteries become depleted. Now, our 'pioneer patients' will be able to take advantage of the latest technology with SenTiva DUO and experience the full benefits of VNS Therapy, without the need to replace their dual-pin lead." (Source – Business Wire) About LivaNova LivaNova PLC is transforming the lives of patients all over the world with its innovation and technological advancements in the medical field, providing clinical and financial support by offering various products and a global reach. Its advanced technologies and revolutionary treatment solutions have benefited healthcare professionals, healthcare systems, and patients worldwide. Headquartered in London (UK), it has about 3,000 employees worldwide and a presence in over 100 countries. Its products work for therapeutic areas like advanced circulatory support, cardiopulmonary, obstructive sleep apnea, heart failure, difficult-to-treat depression (DTD), and drug-resistant epilepsy.

Read More